CIGB-845 is a therapeutic alternative based on the combination of epidermal growth factor (EGF) and growth hormone-releasing peptide 6 (GHRP6) for the treatment of neurodegenerative and cerebrovascular diseases, said the doctor of Sciences Diana Garcia, leader of the Neuroprotection program of the Research Division Biomedical Sciences of the Center for Genetic Engineering and Biotechnology (CIGB).
“So far we have carried out a phase I/II clinical study (Courage), in patients with acute cerebral infarction, which has shown satisfactory results in terms of reduction of disability resulting from cerebral infarction,” Garcia specified.
“Better survival was also seen in patients treated with the combination of epidermal growth factor and growth hormone-releasing peptide 6, compared to those who received standard therapy,” Garcia pointed out.
“Although the results are promising, they must be confirmed in phase III and phase IV clinical studies, which include a greater number of people suffering from this ailment,” García commented.
pgh/llp/mem/joe
